FDA Finalizes Its Biosimilar Manufacturing-Change Rulebook

FDA has finalized its question-and-answer guidance on postapproval manufacturing changes for biosimilar and interchangeable biosimilar products, closing out a commitment it made in the 2022 reauthorization of the Biosimilar User Fee Act. The guidance, posted for public inspection on 9 October 2026 and due in the Federal Register on 13 October, tells CMC and regulatory affairs teams which category a given manufacturing change falls into — and which supplement, if any, it requires before the change can reach product on the market.

Why a reporting tier matters

A biosimilar or interchangeable sponsor that changes a manufacturing process, facility, raw material source or analytical method after approval has to tell FDA — the only open question is how, and how fast the change can take effect. The guidance sorts changes by their potential effect on the product's identity, strength, quality, purity or potency. A change FDA judges to carry substantial potential for an adverse effect needs a Prior Approval Supplement: the sponsor cannot distribute product made under the new process until FDA approves the PAS. A moderate-risk change can go through a CBE-30 supplement, which lets the sponsor distribute 30 days after FDA receives the filing unless the agency objects. Low-risk changes are reported after the fact, in the product's next Annual Report. Sponsors who guess wrong — filing a CBE-30 for a change FDA considers major, for instance — risk a hold or a warning letter over an unauthorized change; guessing conservatively in the other direction means waiting on a PAS review that a lower tier would not have required.

Interchangeables get their own answer

FDA's 2021 version of this Q&A only addressed licensed biosimilars. Interchangeable biosimilars — products FDA has determined can be substituted for the reference product without a prescriber's intervention, depending on state pharmacy law — were left to extrapolate from biosimilar-specific recommendations or fall back on general CMC guidance written for conventional biologics. The finalized guidance folds interchangeables into the same reporting-tier framework explicitly, closing a gap that sponsors and their counsel flagged as a practical complication during the 2024 comment period.

Comparability, shared facilities, and new strengths

• Comparability protocols: the guidance recommends that a comparability protocol submitted in a PAS can reduce the reporting burden for related low-risk CMC changes down the line — file the protocol once, and qualifying future changes may need less than a full PAS.
• Multi-product and contract facilities: it addresses what a sponsor must report when manufacturing moves into a shared production area or a contract manufacturing organization, rather than a dedicated single-product site.
• New dosage forms and strengths: adding a dosage form or strength not previously licensed under the product's 351(k) biologics license application is generally treated as a major change, requiring a PAS.
• Comparability studies: the guidance flags particular attention to comparability at intermediate manufacturing steps and post-manufacturing storage conditions, not only the final drug product, and points sponsors to ICH Q5E for the underlying comparability-study framework.

The clock that produced it

FDA negotiated the BsUFA III commitment to publish this guidance as part of the 2022 user-fee reauthorization covering fiscal years 2023 through 2027. The draft version ran in July 2024 with a comment period that closed in September that year; trade groups, including biosimilar manufacturers, flagged concerns during that window about what they characterized as additional hurdles compared with the general postapproval-change framework that applies to other biologics. The final guidance arrives roughly fifteen months after the draft comment period closed, with FY2027 — the last year covered by the BsUFA III commitment — now underway.

Frequently asked questions

What did FDA finalize, and when?

The guidance for industry "Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers." FDA posted it for public inspection on 9 October 2026, with official Federal Register publication scheduled for 13 October 2026 (FR Doc. 2026-20817).

What does it replace?

It finalizes a draft of the same title FDA issued 23 July 2024 (Docket FDA-2024-D-2581), and it supersedes FDA's September 2021 postapproval-changes Q&A, which covered only licensed biosimilars. This is the first version to also cover licensed interchangeable biosimilars.

How does the reporting-tier framework work?

Postapproval manufacturing changes sort into three categories by potential effect on identity, strength, quality, purity or potency: major changes need a Prior Approval Supplement (PAS); moderate changes can use a CBE-30 supplement; minor changes are reported in the Annual Report.

Why now?

FDA committed to publishing this guidance under the 2022 reauthorization of the Biosimilars User Fee Act (BsUFA III), which covers fiscal years 2023 through 2027.